Prazosin Adrenergic Receptor antagonist

Cat.No.S5780

Prazosin is an α1-blocker that acts as an inverse agonist at alpha-1 adrenergic receptors. It is used to treat hypertension.
Prazosin Adrenergic Receptor antagonist Chemical Structure

Chemical Structure

Molecular Weight: 383.40

Quality Control

Batch: S578001 DMSO]77 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.81%
99.81

Chemical Information, Storage & Stability

Molecular Weight 383.40 Formula

C19H21N5O4

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 19216-56-9 -- Storage of Stock Solutions

Synonyms N/A Smiles COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC

Solubility

In vitro
Batch:

DMSO : 77 mg/mL (200.83 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
α1-adrenergic receptor [1]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05189977 Terminated
Post-traumatic Stress Disorder (PTSD)
Otsuka Pharmaceutical Development & Commercialization Inc.|Iqvia Pty Ltd
September 7 2022 Phase 1
NCT04365257 Terminated
COVID-19
Johns Hopkins University|Fast Grants
May 13 2020 Phase 2
NCT03045016 Completed
Acute Stress Disorder
Hospices Civils de Lyon
April 21 2017 Phase 2
NCT02193256 Completed
Cigarette Smoking|Alcohol Use Disorders
Yale University|National Institute on Alcohol Abuse and Alcoholism (NIAAA)
July 2014 Early Phase 1
NCT01178138 Completed
Continuous Methamphetamine Abuse
University of Arkansas|National Institute on Drug Abuse (NIDA)
December 2009 Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map